Search Results - "FRIMAN, Erika Isaksson"

ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden—a phase III randomised double-blinded placebo-controlled study by Rodriguez-Wallberg, Kenny A, Nilsson, Hanna Pauline, Bergh, Jonas, Malmros, Johan, Ljungman, Per, Foukakis, Theodoros, Stragliotto, Christina Linder, Friman, Erika Isaksson, Linderholm, Barbro, Valachis, Antonis, Andersson, Anne, Harrysson, Sara, Vennström, Lovisa, Frisk, Per, Mörse, Helena, Eloranta, Sandra

“…BackgroundGonadotropin-releasing hormone agonists (GnRHa) cotreatment used to transiently suppress ovarian function during chemotherapy to prevent ovarian…”
Get full text

Severe Photo Toxicity Recalled by Docetaxel by Johansson, Emma K., Krynitz, Britta, Holmsten, Magnus, Klockhoff, Kerstin, Isaksson Friman, Erika, Xie, Hanjing

“…Photo-recall phenomenon is a rarely recognized adverse event of chemotherapeutic agents. The physiopathology of this entity is unclear. We have reported a…”
Get full text

Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer by Brandberg, Yvonne, Andersson, Anne, Bjohle, Judith, Bosch, Ana, Carlsson, Lena, Dreifaldt, Ann Charlotte, Einbeigi, Zakaria, Fredholm, Hanna, Isaksson-Friman, Erika, Foukakis, Theodoros, Elinder, Ellinor, Hellstrom, Mats, Johansson, Hemming, Lekberg, Tobias, Lindman, Henrik, Bergh, Jonas C. S., Hatschek, Thomas

“…Abstract only 583 Background: Neoadjuvant therapy combining docetaxel, trastuzumab and pertuzumab (DTP) was compared to trastuzumab emtansine (T-DM1) in the…”
Get full text

Risk Factors for Hormone Receptor-Defined Breast Cancer in Postmenopausal Women by ROSENBERG, Lena U, EINARSDOTTIR, Kristjana, FRIMAN, Erika Isaksson, WEDREN, Sara, DICKMAN, Paul W, HALL, Per, MAGNUSSON, Cecilia

“…The effect of classic breast cancer risk factors on hormone receptor-defined breast cancer is not fully clarified. We explored these associations in a Swedish…”
Get full text

Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial by Matikas, Alexios, Johansson, Hemming, Grybäck, Per, Bjöhle, Judith, Acs, Balazs, Boyaci, Ceren, Lekberg, Tobias, Fredholm, Hanna, Elinder, Ellinor, Margolin, Sara, Isaksson-Friman, Erika, Bosch, Ana, Lindman, Henrik, Adra, Jamila, Andersson, Anne, Agartz, Susanne, Hellström, Mats, Zerdes, Ioannis, Hartman, Johan, Bergh, Jonas, Hatschek, Thomas, Foukakis, Theodoros

“…PREDIX HER2 is a randomized Phase II trial that compared neoadjuvant docetaxel, trastuzumab, and pertuzumab (THP) with trastuzumab emtansine (T-DM1) for…”
Get full text

The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial by Zhu, Yajing, Zerdes, Ioannis, Matikas, Alexios, Cruz, Ivette Raices, Bergqvist, Mattias, Elinder, Ellinor, Bosch, Ana, Lindman, Henrik, Einbeigi, Zakaria, Andersson, Anne, Carlsson, Lena, Dreifaldt, Ann Charlotte, Isaksson-Friman, Erika, Hellstrom, Mats, Johansson, Hemming, Wang, Kang, Bergh, Jonas C. S., Hatschek, Thomas, Foukakis, Theodoros

“…Background Thymidine kinase 1 (TK1) plays a pivotal role in DNA synthesis and cellular proliferation. TK1 has been studied as a prognostic marker and as an…”
Get full text

Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial by Matikas, Alexios, Johansson, Hemming, Grybäck, Per, Bjöhle, Judith, Lekberg, Tobias, Fredholm, Hanna, Acs, Balazs, Elinder, Ellinor, Isaksson-Friman, Erika, Agartz, Susanne, Hellstrom, Mats, Zerdes, Ioannis, Hartman, Johan, Bergh, Jonas C. S., Hatschek, Thomas, Foukakis, Theodoros

“…593 Background: Abundance of tumor infiltrating lymphocytes (TIL) is prognostic in early HER2-positive breast cancer (BC). Response to neoadjuvant therapy…”
Get full text

Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial by Zhu, Yajing, Wang, Kang, Zerdes, Ioannis, Matikas, Alexios, Bergqvist, Mattias, Elinder, Ellinor, Bosch, Ana, Lindman, Henrik, Einbeigi, Zakaria, Andersson, Anne, Carlsson, Lena, Dreifaldt, Ann Charlotte, Isaksson-Friman, Erika, Hellstrom, Mats, Johansson, Hemming, Bergh, Jonas C. S., Hatschek, Thomas, Foukakis, Theodoros

“…e12598 Background: Thymidine kinase 1 (TK1) plays a pivotal role in DNA synthesis and cellular proliferation. TK1 has been studied as a prognostic marker and…”
Get full text

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial by Hatschek, Thomas, Foukakis, Theodoros, Bjöhle, Judith, Lekberg, Tobias, Fredholm, Hanna, Elinder, Ellinor, Bosch, Ana, Pekar, Gyula, Lindman, Henrik, Schiza, Aglaia, Einbeigi, Zakaria, Adra, Jamila, Andersson, Anne, Carlsson, Lena, Dreifaldt, Ann Charlotte, Isaksson-Friman, Erika, Agartz, Susanne, Azavedo, Edward, Grybäck, Per, Hellström, Mats, Johansson, Hemming, Maes, Claudia, Zerdes, Ioannis, Hartman, Johan, Brandberg, Yvonne, Bergh, Jonas

“…Trastuzumab emtansine (T-DM1) is presently approved for treatment of advanced breast cancer and after incomplete response to neoadjuvant therapy, but the…”
Get more information

One-year follow-up of health-related quality of life in the Swedish PREDIX HER 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2 positive breast cancer by Brandberg, Yvonne, Foukakis, Theodoros, Andersson, Anne, Bjohle, Judith, Bosch, Ana, Carlsson, Lena, Einbeigi, Zakaria, Fredholm, Hanna, Isaksson-Friman, Erika, Hellstrom, Mats, Johansson, Hemming, Lekberg, Tobias, Lindman, Henrik, Bergh, Jonas C. S., Hatschek, Thomas

“…Abstract only 590 Background: Neoadjuvant therapy combining docetaxel, trastuzumab and pertuzumab (DTP) was compared to trastuzumab emtansine (T-DM1) in the…”
Get full text

Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard? by Bergh, Jonas C. S., Andersson, Anne, Bjohle, Judith, Bosch, Ana, Carlsson, Lena, Dreifaldt, Ann Charlotte, Einbeigi, Zakaria, Fredholm, Hanna, Isaksson-Friman, Erika, Foukakis, Theodoros, Elinder, Ellinor, Hellstrom, Mats, Johansson, Hemming, Lekberg, Tobias, Lindman, Henrik, Maes, Claudia, Brandberg, Yvonne, Hatschek, Thomas

“…Abstract only 501 Background: Neoadjuvant therapy produces high rates of pathological complete response (pCR) and is the standard of care in HER2 positive…”
Get full text

Abstract P5-02-20: Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trial by Wang, Kang, Zhu, Yajing, Zerdes, Ioannis, Matikas, Alexios, Sifakis, Emmanouil, Salgkamis, Dimitrios, Bjöhle, Judith, Elinder, Ellinor, Margolin, Sara, Campos, Ana Bosch, Pekar, Gyula, Lindman, Henrik, Schiza, Aglaia, Einbeigi, Zakaria, Adra, Jamila, Andersson, Anne, Carlsson, Lena, Dreifaldt, Ann Charlotte, Isaksson-Friman, Erika, Agartz, Susanne, Johansson, Hemming, Hellström, Mats, Azavedo, Edward, Hartman, Johan, Bergh, Jonas, Hatschek, Thomas, Foukakis, Theodoros

“…Background: The PREDIX HER2 trial compared standard neoadjuvant therapy with 6 cycles of docetaxel, trastuzumab, and pertuzumab (DTP), versus 6 cycles of…”
Get full text

Adverse reactions to anti-hormonal therapy affects adherence by von Wachenfeldt, Anna, Andersson, Anne, Fornander, Tommy, Isaksson Friman, Erika, Johnsson, Aina, Uddbom, Eleonor, Uttermalm, Anna-Carin

Get more information

Severe Photo Toxicity Recalled by Docetaxel by Johansson, Emma K, Krynitz, Britta, Holmsten, Magnus, Klockhoff, Kerstin, Isaksson Friman, Erika, Xie, Hanjing

Get full text